Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 29;6:e33415. doi: 10.7554/eLife.33415

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017, Garofalo et al

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

PMC Copyright notice

Figure 5. — (a) Left: mice housed in SE were infused for 7 days in the striatum, with vehicle or IL-15 through micro-osmotic pumps, starting 10 days after GL261 cell transplantation, as described in the scheme. Right: expression of IFN-γ in CLH and ILH of GL261-bearing mice treated with vehicle or Ab anti-NK1.1 as indicated, implanted with osmotic pumps releasing IL-15 or vehicle (n = 5, **p<0.01, one-way ANOVA). (b) RT-PCR of anti- (Chil3, Mrc1, Arg1, Retnla) and pro-inflammatory (Cd86, Nos2, Tnfa, Il1b) genes in CD11b⁺ cells sorted from ILH and CLH of GL261-bearing mice treated with IL-15 or vehicle. Data are expressed as mean ± S.E.M., *p<0.05 **p<0.01 versus CLH, one-way ANOVA; n = 4. (c) Myeloid cell activation (CD68) and infiltration (F4/80) in glioma mass in mice treated with IL-15 or vehicle, as shown in (a), analyzed at the end of treatment (17 days after glioma transplantation). Graph bars represent the mean (± S.E.M.) area expressed as percentage of total tumor area. Representative immunofluorescences are shown on the right (scale bar, 100 μm) (**p=0.002 *p=0.011 Student’s t-test; n = 4 mice per conditions). (d) RT-PCR of anti- and pro-inflammatory genes in CD11b⁺ cells isolated from ILH and CLH of GL261-bearing mice in vehicle and Ab-anti-NK1.1-treated mice, upon IL-15 or vehicle infusion, as shown in (a). Data are expressed as the mean ± S.E.M., **p<0.01 versus CLH, one-way ANOVA; n = 4. (e) Analysis of tumor volumes (expressed as mm³ ± S.E.M.) in wt or Il15ra^–/– mice, housed in SE or EE; n = 5; **p<0.01, two-way ANOVA). Representative coronal sections are shown on the right. (f) RT-PCR of anti- and pro-inflammatory genes in CD11b⁺ cells sorted from ILH and CLH in Il15ra^–/– mice, housed in SE or EE. Data are the means ± S.E.M., **p<0.01 versus CLH, one-way ANOVA; n = 4–5. (g) RT-PCR of Il15 mRNA in CD11b⁺ cells sorted from ILH and CLH of GL261-bearing mice treated with BDNF or vehicle. Data are the mean ± S.E.M., *p<0.05 versus CLH, one-way ANOVA; n = 5. Above: scheme of striatal infusion of vehicle or BDNF with micro-osmotic pumps starting 10 days after glioma cell transplantation and lasting 7 days, in SE mice. (h) RT-PCR of Il15 mRNA in CD11b⁺ cells isolated from ILH and CLH in wt or Bdnf^+/^– GL261 bearing mice, housed in SE or EE. Data are the mean ± S.E.M., *p<0.05 versus CLH, one-way ANOVA, n = 4. (i) RT-PCR of Il15 mRNA in primary mouse microglia stimulated with vehicle, LPS + IFNγ or IL-4 or in co-culture with GL261 for 24 h, in the presence or absence of BDNF. Data are expressed as the mean ± S.E.M., *p<0.05 **p<0.01, one-way ANOVA, n = 10.

Figure 5—figure supplement 1. — (a) Left: mice housed in SE were infused for 7 days in the striatum, with vehicle or IL-15 through micro-osmotic pumps, starting 10 days after GL261 cell transplantation, as described in the scheme. Right: expression of IFN-γ in CLH and ILH of GL261-bearing mice treated with vehicle or Ab anti-NK1.1 as indicated, implanted with osmotic pumps releasing IL-15 or vehicle (n = 5, **p<0.01, one-way ANOVA). (b) RT-PCR of anti- (Chil3, Mrc1, Arg1, Retnla) and pro-inflammatory (Cd86, Nos2, Tnfa, Il1b) genes in CD11b⁺ cells sorted from ILH and CLH of GL261-bearing mice treated with IL-15 or vehicle. Data are expressed as mean ± S.E.M., *p<0.05 **p<0.01 versus CLH, one-way ANOVA; n = 4. (c) Myeloid cell activation (CD68) and infiltration (F4/80) in glioma mass in mice treated with IL-15 or vehicle, as shown in (a), analyzed at the end of treatment (17 days after glioma transplantation). Graph bars represent the mean (± S.E.M.) area expressed as percentage of total tumor area. Representative immunofluorescences are shown on the right (scale bar, 100 μm) (**p=0.002 *p=0.011 Student’s t-test; n = 4 mice per conditions). (d) RT-PCR of anti- and pro-inflammatory genes in CD11b⁺ cells isolated from ILH and CLH of GL261-bearing mice in vehicle and Ab-anti-NK1.1-treated mice, upon IL-15 or vehicle infusion, as shown in (a). Data are expressed as the mean ± S.E.M., **p<0.01 versus CLH, one-way ANOVA; n = 4. (e) Analysis of tumor volumes (expressed as mm³ ± S.E.M.) in wt or Il15ra^–/– mice, housed in SE or EE; n = 5; **p<0.01, two-way ANOVA). Representative coronal sections are shown on the right. (f) RT-PCR of anti- and pro-inflammatory genes in CD11b⁺ cells sorted from ILH and CLH in Il15ra^–/– mice, housed in SE or EE. Data are the means ± S.E.M., **p<0.01 versus CLH, one-way ANOVA; n = 4–5. (g) RT-PCR of Il15 mRNA in CD11b⁺ cells sorted from ILH and CLH of GL261-bearing mice treated with BDNF or vehicle. Data are the mean ± S.E.M., *p<0.05 versus CLH, one-way ANOVA; n = 5. Above: scheme of striatal infusion of vehicle or BDNF with micro-osmotic pumps starting 10 days after glioma cell transplantation and lasting 7 days, in SE mice. (h) RT-PCR of Il15 mRNA in CD11b⁺ cells isolated from ILH and CLH in wt or Bdnf^+/^– GL261 bearing mice, housed in SE or EE. Data are the mean ± S.E.M., *p<0.05 versus CLH, one-way ANOVA, n = 4. (i) RT-PCR of Il15 mRNA in primary mouse microglia stimulated with vehicle, LPS + IFNγ or IL-4 or in co-culture with GL261 for 24 h, in the presence or absence of BDNF. Data are expressed as the mean ± S.E.M., *p<0.05 **p<0.01, one-way ANOVA, n = 10.